Comparison of carboplatin plus etoposide with amrubicin monotherapy for extensive-disease small cell lung cancer in the elderly and patients with poor performance status.

Satoshi IgawaMasayuki ShirasawaTakahiro OzawaNoriko NishinaritaYuriko OkumaTaihei OnoAi SugimotoShintaro KurahayashiKeisuke SugitaHideyuki SoneTomoya FukuiHisashi MitsufujiMasaru KubotaMasato KatagiriJiichiro SasakiKatsuhiko Naoki

Published in: Thoracic cancer (2018)

CE remains a suitable first-line treatment for ED-SCLC in elderly patients or those with poor PS in comparison with AMR.

Keyphrases

small cell lung cancer
emergency department
open label
randomized controlled trial
combination therapy
brain metastases
community dwelling
clinical evaluation